IGFBP-3 level

Reference

Reference
Belobrajdic DP, Priebe IK, Forbes B, Flyvbjerg A, Chen JW, Cosgrove LJ, Frystyk J and Saunders IW, 2008, Growth Hormone and IGF Res, 18, 198-204 , Assessing the potential usefulness of IGF-related peptides and adiponectin for predicting disease risk

Scoring

Total Score

C8,13

Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis C
9. Normality B
10. Variance Homogeneity A
11. ANOVA A
12. CI A
13. No of Results C
14. Concentrations A
15. Total Score C8,13
Comment C8, C13

Item Details

Parameter Score
Matrix Serum
Measurand IGFBP-3 level
Unit mg / L
Overall Analytical Principle Method Immunoinhibition
Number of Subjects 10
Number of Subjects included in BV estimation 10
Ethinicity Unknown
Age Mean / Median 38.0
Age Min 22.0
Age Max 53.0
Age SD
Number of Males 6
Number of Females 4
State of Well Being
Healthy (excl pregnant)
Diseases
Study Duration Length 5
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time: 8:00
End Time: 14:00
Number of Samples 5
Average Number of Samples Used for BV Estimation 5.0
Average Number of Replicates 2.0
Estimates of CVi 0.002
Calculated Confidence Intervals of CVi Lower: 0.00, Upper: 4.14
Estimates of CVg 0.003
Calculated Confidence Intervals of CVg Lower: 0.00, Upper: 3.19
Analytical CV 7.0
Calculated Confidence Intervals of Analytical CV Lower: 5.86, Upper: 8.70
Measurand Mean 4960.0
Measurand Min
Measurand Max
Measurand SD 4960.0

Coding